Arkadios Wealth Advisors Purchases 288 Shares of Insulet Co. (NASDAQ:PODD)

Arkadios Wealth Advisors lifted its position in shares of Insulet Co. (NASDAQ:PODD) by 28.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,286 shares of the medical instruments supplier’s stock after acquiring an additional 288 shares during the quarter. Arkadios Wealth Advisors’ holdings in Insulet were worth $299,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in PODD. Blue Trust Inc. increased its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Insulet in the second quarter valued at about $32,000. UMB Bank n.a. increased its holdings in Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. CVA Family Office LLC increased its holdings in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 145 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its holdings in Insulet by 159.2% in the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 156 shares during the last quarter.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of research analyst reports. Barclays boosted their target price on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. UBS Group boosted their target price on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. BTIG Research boosted their target price on Insulet from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Finally, Raymond James boosted their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $242.29.

Insulet Stock Up 0.4 %

PODD stock opened at $231.53 on Friday. Insulet Co. has a fifty-two week low of $128.68 and a fifty-two week high of $243.98. The stock has a market capitalization of $16.23 billion, a P/E ratio of 42.10, a P/E/G ratio of 4.36 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The business has a 50-day moving average of $226.09 and a 200-day moving average of $200.78.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. During the same quarter in the previous year, the company posted $0.38 EPS. The business’s revenue was up 23.2% on a year-over-year basis. On average, sell-side analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.